D-amphetamine and antipsychotic drug effects on latent inhibition in mice lacking dopamine D2 receptors

Neuropsychopharmacology

Volumn 38, Issue 8, 2013, Pages 1512-1520

  Bay Richter, C ^a   O'Callaghan, M J ^a   Mathur, N ^a   O'Tuathaigh, C M P ^b   Heery, D M ^a   Fone, K C F ^a   Waddington, J L ^b   Moran, P M ^a  

^a UNIVERSITY OF NOTTINGHAM   (United Kingdom)

^b ROYAL COLLEGE OF SURGEONS IN IRELAND   (Ireland)

Author keywords

antipsychotics; D amphetamine; dopamine D1 receptor; dopamine D2 receptor; latent inhibition; mice

Indexed keywords

8 BROMO 2,3,4,5 TETRAHYDRO 3 METHYL 5 PHENYL 1H 3 BENZAZEPIN 7 OL; CLOZAPINE; DEXAMPHETAMINE; DOPAMINE 2 RECEPTOR; HALOPERIDOL;

ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; DRUG ANTAGONISM; DRUG EFFECT; FEMALE; HYPERACTIVITY; LATENT INHIBITION; LOCOMOTION; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL;

ANIMALS; ANTIPSYCHOTIC AGENTS; DEXTROAMPHETAMINE; FEMALE; INHIBITION (PSYCHOLOGY); LEARNING; MALE; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; RECEPTORS, DOPAMINE D2; TIME FACTORS;

EID: 84879417282     PISSN: 0893133X     EISSN: 1740634X     Source Type: Journal    
DOI: 10.1038/npp.2013.50     Document Type: Article

References (70)

1. Angrist B, Rotrosen J, Gershon S (1980). Responses to apomor-phine, amphetamine, and neuroleptics in schizophrenic subjects. Psychopharmacology 67: 31-38. (Pubitemid 10173717)
2. Barak S, Weiner I (2011). The M/M4 preferring agonist xanomeline reverses amphetamine-, MK801- and scopolamine-induced abnormalities of latent inhibition: putative efficacy against positive, negative and cognitive symptoms in schizophrenia. Int J Neuropsychopharmacol 14: 1233-1246.
3. Bay-Richter C, O'Tuathaigh CMP, O'Sullivan G, Heery DM, Waddington JL, Moran PM (2009). Enhanced latent inhibition in dopamine receptor-deficient mice is sex-specific for the D-1 but not D-2 receptor subtype: implications for antipsychotic drug action. Int J Neuropsychopharmacol 12: 403-414.
4. Black M, Varty G, Aarad M, Barak S, DeLevie A, Boulay D et al (2009). Procognitive and antipsychotic efficacy of glycine transport 1 inhibitors (GlyT1) in acute and neurodevelopmental models of schizophrenia: latent inhibition studies in the rat. Psychopharmacology 202: 385-396.
5. Boulay D, Depoortere R, Perrault G, Borrelli E, Sanger DJ (1999). Dopamine D-2 receptor knock-out mice are insensitive to the hypolocomotor and hypothermic effects of dopamine D-2/D-3 receptor agonists. Neuropharmacology 38: 1389-1396. (Pubitemid 29333155)
6. Broersen LM, Feldon J, Weiner I (1999). Dissociative effects of apomorphine infusions into the medial prefrontal cortex of rats on latent inhibition, prepulse inhibition and amphetamine-induced locomotion. Neuroscience 94: 39-46. (Pubitemid 29457595)
7. Chang T, Meyer U, Feldon J, Yee BK (2007). Disruption of the US pre-exposure effect and latent inhibition in two-way active avoidance by systemic amphetamine in C57BL/6 mice. Psycho-pharmacology 191: 211-221. (Pubitemid 46354609)
8. Cohen BM, Lipinski JF (1986). In vivo potencies of antipsychotic-drugs in blocking alpha-1 noradrenergic and dopamine D2 receptors implications for drug mechanisms of action. Life Sci 39: 2571-2580.
9. Cole SO (1978). Brain mechanisms of amphetamine-induced anorexia, locomotion, and stereotypy review. Neurosci Biobehav Rev 2: 89-100. (Pubitemid 9025706)
10. Crawford CA, Drago J, Watson JB, Levine MS (1997). Effects of repeated amphetamine treatment on the locomotor activity of the dopamine D1A-deficient mouse. Neuroreport 8: 2523-2527. (Pubitemid 27308454)
11. Dencker B, Wortwein G, Weikop P, Jeon J, Thomsen M, Sager TN et al (2011). Involvement of a subpopulation of Neuronal M4 Muscarinic Acetylcholine receptors in the antipsychotic effect of the Muscarinic receptor Agonist Xanomeline. J Neurosci 31: 5905-5908.
12. Drago J, Gerfen CR, Lachowicz JE, Steiner H, Hollon TR, Love PE et al (1994). Altered striatal function in a mutant mouse lacking D-1a dopamine-receptors. Proc Natl Acad Sci US A 91: 12564-12568.
13. Fleischhacker WW, Meise U, Gunther V, Kurz M (1994). Compliance with antipsychotic drug-treatment influence of side-effects. Acta Psychiatr Scand 89: 11-15.
14. Gray JA, Feldon J, Rawlins JNP, Smith AD, Hemsley DR (1991). The neuropsychology of schizophrenia. Behav Brain Sci 14: 1-19.
15. Gray NS, Hemsley DR, Gray JA (1992). Abolition of latent inhibition in acute, but not chronic, schizophrenics. Neurol Psychiatry Brain Res 1: 83-89. (Pubitemid 24025553)
16. Howes OD, Egerton A, Allan V, McGuire P, Stokes P, Kapur S (2009). Mechanisms underlying psychosis and antipsychotic treatment response in schizophrenia: insights from PET and SPECT imaging. Curr Pharm Design 15: 2550-2559.
17. Hutchison KE, Swift R (1999). Effect of d-amphetamine on prepulse inhibition of the startle reflex in humans. Psychophar-macology 143: 394-400. (Pubitemid 29222485)
18. Javitt DC (2012). Glycine transport inhibitors in the treatment of schizophrenia. Handbook Exp Pharmacol 213: 367-399.
19. Joseph MH, Peters SL, Gray JA (1993). Nicotine blocks latent inhibition in rats evidence for a critical role of increased functional-activity of dopamine in the mesolimbic system at conditioning rather than preexposure. Psychopharmacology 110: 187-192. (Pubitemid 23029448)
20. Josselyn SA, Miller R, Beninger RJ (1997). Behavioral effects of clozapine and dopamine receptor subtypes. Neurosci Biobehav Rev 21: 531-558. (Pubitemid 27458799)
21. Kapur S, Mizrahi R, Li M (2005). From dopamine to salience to psychosis - linking biology, pharmacology and phenomenology of psychosis. Schizophr Res 79: 59-68. (Pubitemid 41362593)
22. Kapur S, Seeman P (2001). Does fast dissociation from the dopamine D-2 receptor explain the action of atypical anti-psychotics?: a new hypothesis. Am J Psychiatry 158: 360-369. (Pubitemid 32205190)
23. Kapur S, Zipursky R, Jones C, Remington G, Houle S (2000). Relationship between dopamine D-2 occupancy, clinical response, and side effects: a double-blind PET study of first-episode schizophrenia. Am J Psychiatry 157: 514-520. (Pubitemid 30191189)
24. Kelly MA, Low MJ, Rubinstein M, Phillips TJ (2008). Role of dopamine D1-like receptors in methamphetamine locomotor responses of D2 receptor knockout mice. Genes Brain Behav 7: 568-577. (Pubitemid 351991491)
25. Kelly MA, Rubinstein M, Asa SL, Zhang G, Saez C, Bunzow JR et al (1997). Pituitary lactotroph hyperplasia and chronic hyperpro-lactinemia in dopamine D2 receptor-deficient mice. Neuron 19: 103-113. (Pubitemid 27332997)
26. Kelly MA, Rubinstein M, Phillips TJ, Lessov CN, Burkhart-Kasch S, Zhang G et al (1998). Locomotor activity in D2 dopamine receptor-deficient mice is determined by gene dosage, genetic background, and developmental adaptations. J Neurosci 18: 3470-3479. (Pubitemid 28186038)
27. Killcross AS, Dickinson A, Robbins TW (1994). Amphetamine-induced disruptions of latent inhibition are reinforcer mediated implications for animal-models of schizophrenic attentional dysfunction. Psychopharmacology 115: 185-195. (Pubitemid 24207781)
28. Lacroix L, Broersen LM, Feldon J, Weiner I (2000). Effects of local infusions of dopaminergic drugs into the medial prefrontal cortex of rats on latent inhibition, prepulse inhibition and amphetamine induced activity. Behav Brain Res 107: 111-121.
29. Lipina T, Labrie V, Weiner I, Roder J (2005). Modulators of the glycine site on NMDA receptors, D-serine and ALX 5407, display similar beneficial effects to clozapine in mouse models of schizophrenia. Psychopharmacology 179: 54-67. (Pubitemid 40576692)
30. Liu Y, Aragona BJ, Young KA, Dietz DM, Kabbaj M, Mazei-Robison M et al (2010). Nucleus accumbens dopamine mediates amphetamine-induced impairment of social bonding in a monogamous rodent species. Proc Natl Acad Sci USA 107: 1217-1222.
31. Liu Y, Young KA, Curtis JT, Aragona BJ, Wang ZX (2011). Social bonding decreases the rewarding properties of amphetamine through a dopamine D1 receptor-mediated mechanism. J Neurosci 31: 7960-7966.
32. Lubow RE (2005). Construct validity of the animal latent inhibition model of selective attention deficits in schizophrenia. Schizophr Bull 31: 139-153. (Pubitemid 41214363)
33. Maier W, Mossner R, Quednow BB, Wagner M, Hurlemann R (2008). From genes to psychoses and back: the role of the 5HT2 alpha-receptor and prepulse inhibition in schizophrenia. Eur Archiv Psychiatry Clin Neurosci 258: 40-43.
34. Mansbach RS, Geyer MA, Braff DL (1988). Dopaminergic stimulation disrupts sensorimotor gating in the rat. Psychophar-macology 94: 507-514. (Pubitemid 18087401)
35. Marriott AS (1968). Effects of amphetamine caffeine and methylphenidate on locomotor activity of rats in an unfamiliar environment. Int J Neuropharmacol 7: 487-48.
36. Melo LL, Pereira EC, Pagini CH, Coimbra NC, Brandão ML, Ferrari EA (2009). Effects of microinjections of apomorphine and haloperidol into the inferior colliculus on the latent inhibition of the conditioned emotional response. Exp Neurol 216: 16-21.
37. Meltzer HY, Matsubara S, Lee JC (1989). Classification of typical and atypical antipsychotic-drugs on the basis of dopamine D-1, D-2 and serotonin2 Pki values. J Pharmacol Exp Therap 251: 238-246.
38. Meyer U, Chang DLT, Feldon J, Yee BK (2004). Expression of the CS- and US-pre-exposure effects in the conditioned taste aversion paradigm and their abolition following systemic amphetamine treatment in C57BL6/J mice. Neuropsychopharma-cology 29: 2140-2148. (Pubitemid 39578904)
39. Miller R (2009). Mechanisms of action of antipsychotic drugs of different classes, refractoriness to therapeutic effects of classical neuroleptics, and individual variation in sensitivity to their actions: PART II. Curr Neuropharmacol 7: 315-330.
40. Miller R, Wickens JR, Beninger RJ (1990). Dopamine D-1-receptor and D-2-receptor in relation to reward and performance a case for the D-1-receptor as a primary site of therapeutic action of neuroleptic drugs. Progr Neurobiol 34: 143-183. (Pubitemid 20066616)
41. Miyamoto S, Duncan GE, Marx CE, Lieberman JA (2005). Treatments for schizophrenia: a critical review of pharmacology and mechanisms of action of antipsychotic drugs. Mol Psychiatr 10: 79-104. (Pubitemid 40139590)
42. Moran PM, Fischer TR, Hitchcock JM, Moser PC (1996). Effects of clozapine on latent inhibition in the rat. Behav Pharmacol 7: 42-48. (Pubitemid 26051784)
43. Moser PC, Hitchcock JM, Lister S, Moran PM (2000). The pharmacology of latent inhibition as an animal model of schizophrenia. Brain Res Rev 33: 275-307.
44. Natesan S, Reckless GE, Nobrega JN, Fletcher PJ, Kapur S (2006). Dissociation between in vivo occupancy and functional antagonism of dopamine D-2 receptors: comparing aripiprazole to other antipsychotics in animal models. Neuropsychopharmacol-ogy 31: 1854-1863.
45. Nelson AJ, Thur KE, Cassaday HJ (2012). Dopamine D1 receptor involvement in latent inhibition and overshadowing. Int J Neuropharmacol 15: 1513-1523.
46. Olney JW, Newcomer JW, Farber NB (1999). NMDA receptor hypofunction model of schizophrenia. J Psychiatric Res 33: 523-533.
47. O'Tuathaigh CMP, Moran PM (2002). Evidence for dopamine D-1 receptor involvement in the stimulus selection task: overshadowing in the rat. Psychopharmacology 162: 225-231. (Pubitemid 34762280)
48. Patil ST, Zhang L, Martenyi F, Lowe SL, Jackson KA, Andreev BV et al (2007). Activation of mGlu2/3 receptors as a new approach to treat schizophrenia: a randomized phase 2 clinical trial. Nat Med 13: 1102-1107. (Pubitemid 47517511)
49. Ralph RJ, Varty GB, Kelly MA, Wang YM, Caron MG, Rubinstein M et al (1999). The dopamine D-2, but not D-3 or D-4, receptor subtype is essential for the disruption of prepulse inhibition produced by amphetamine in mice. J Neurosci 19: 4627-4633. (Pubitemid 29241110)
50. Ralph-Williams RJ, Lehmann-Masten V, Otero-Corchon V, Low MJ, Geyer MA (2002). Differential effects of direct and indirect dopamine agonists on prepulse inhibition: a study in D1 and D2 receptor knock-out mice. J Neurosci 22: 9604-9611. (Pubitemid 35356202)
51. Schmidt CJ, Fadayel GM (1996). Regional effects of MK-801 on dopamine release: effects of competitive NMDA or 5-HT2A receptor blockade. J Pharmacol Exp Therap 277: 1541-1549.
52. Schmidt CJ, Sorensen SM, Kehne JH, Carr AA, Palfreyman MG (1995). The role of 5-Ht2a receptors in antipsychotic activity. Life Sci 56: 2209-2222.
53. Schmitz Y, Lee CJ, Schmauss C, Gonon F, Sulzer D (2001). Amphetamine distorts stimulation-dependent dopamine overflow: effects on D2 autoreceptors, transporters, and synaptic vesicle stores. J Neurosci 21: 5916-5924. (Pubitemid 32737724)
54. Seeman P, Guan HC (2009). Glutamate agonist LY404, 039 for treating schizophrenia has affinity for the dopamine D2(high) receptor. Synapse 63: 935-939.
55. Seeman P, Lee T, Chauwong M, Wong K (1976). Antipsychotic drug doses and neuroleptic-dopamine receptors. Nature 261: 717-719.
56. Shao F, Han X, Li N, Wang W (2010). Adolescent chronic apomorphine treatment impairs latent inhibition and reduces prefrontal cortex mGluR5 receptor expression in adult rats. Eur J Pharmacol 649: 202-205.
57. Shekhar A, Potter WZ, Lightfoot J, Lienmemann J, Dube S, Mallinckrodt C et al (2008). Selective muscarinic receptor agonist xanomeline as a novel treatment approach for schizophrenia. Am J Psychiatry 165: 1033-1039.
58. Shi WX, Pun CL, Zhang XX, Jones MD, Bunney BS (2000). Dual effects of D-amphetamine on dopamine neurons mediated by dopamine and nondopamine receptors. J Neurosci 20: 3504-3511. (Pubitemid 30263765)
59. Vezina P (1996). D1 dopamine receptor activation is necessary for the induction of sensitization by amphetamine in the ventral tegmental area. J Neurosci 16: 2411-2420. (Pubitemid 26154350)
60. Waddington JL, O'Tuathaigh C, O'Sullivan G, Tomiyama K, Koshikawa N, Croke DT (2005). Phenotypic studies on dopamine receptor subtype and associated signal transduction mutants: insights and challenges from 10 years at the psychopharmacology-molecular biology interface. Psychophar-macology 181: 611-638. (Pubitemid 41400749)
61. Watts VJ, Lawler CP, Fox DR, Neve KA, Nichols DE, Mailman RB (1995). Lsd and structural analogs pharmacological evaluation at D-1 dopamine-receptors. Psychopharmacology 118: 401-409.
62. Weiner I (2003). The 'two-headed' latent inhibition model of schizophrenia: modeling positive and negative symptoms and their treatment. Psychopharmacology 169: 257-297. (Pubitemid 37264944)
63. Weiner I, Arad M (2009). Using the pharmacology of latent inhibition to model domains of pathology in schizophrenia and their treatment. Behav Brain Res 204: 369-386.
64. Weiner I, Bernasconi E, Broersen LM, Feldon J (1997). Amphetamine-induced disruption of latent inhibition depends on the nature of the stimulus. Behav Pharmacol 8: 442-457. (Pubitemid 127503073)
65. Weiner I, Lubow RE, Feldon J (1988). Disruption of latent inhibition by acute administration of low doses of amphetamine. Pharmacol Biochem 30: 871-878. (Pubitemid 19270645)
66. Xu M, Guo YH, Vorhees CV, Zhang JH (2000). Behavioral responses to cocaine and amphetamine administration in mice lacking the dopamine D1 receptor. Brain Res 852: 198-207. (Pubitemid 30017751)
67. 2 receptor occupancy and clinical improvement in schizophrenia: a meta-analysis. Schizophr Res 140: 214-220.
68. Young AMJ, Joseph MH, Gray JA (1992). Increased dopamine release in vivo in nucleus accumbens and caudate nucleus of the rat during drinking: a microdialysis study. Neuroscience 48: 871-876.
69. Young AMJ, Moran PM, Joseph MH (2005). The role of dopamine in conditioning and latent inhibition: What, when, where and how? Neurosci Biobehav Rev 29: 963-976. (Pubitemid 41097395)
70. Zelikowsky M, Fanselow MS (2010). Opioid regulation of pavlovian overshadowing in fear conditioning. Behav Neurosci 124: 510-519.